Chimela Ohaji

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Van K. Morris, Mohamed E. Salem, Halla Nimeiri et al. · The Lancet Oncology · 2017 · 393 citations

Medicine, Oncology, Pharmacotherapy +12

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

Vivek Subbiah, Caitlin McMahon, Shreyaskumar Patel et al. · Journal of Hematology & Oncology · 2015 · 101 citations · Full text

Medicine, Gynecology, Oncology +17

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Rachna T. Shroff, Mark Yarchoan, Ashley O’Connor et al. · British Journal of Cancer · 2017 · 91 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).

Van K. Morris, Kristen K. Ciombor, Mohamed E. Salem et al. · Journal of Clinical Oncology · 2016 · 23 citations · Full text

Medicine, Immunology, Oncology +17

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

Ahmed O. Kaseb, S. Cheenu Kappadath, Sunyoung S. Lee et al. · Journal of Hepatocellular Carcinoma · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +17